Clinical Trials Logo

Clinical Trial Summary

The study sought to observe the effects of optimal dose of ticagrelor(90 mg qd)ticagrelor and double standard-dose clopidogrel on platelet reactivity in coronary heart disease patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel.

HTPR with clopidogrel administration in coronary heart disease (CHD) patients has associated with an increased risk of adverse events. Newer P2Y12 inhibitors ticagrelor (90mg BID) provide stronger platelet inhibition compared with clopidogrel, but a low-dose of ticagrelor (90mg QD) has not been previously studied in Chinese CHD patients with HTPR.


Clinical Trial Description

Dual antiplatelet therapy (DAPT) with aspirin and P2Y12 receptor inhibitor has been the mainstay for the prevention of recurrent ischemic events in ACS patients and in those undergoing PCI. However, clopidogrel shows major individual variation in its antiplatelet effect in association with an increased incidence of ischemic events and stent thrombosis in patients with High on-treatment platelet reactivity (HTPR). There are several possible mechanisms of clopidogrel response variability or "resistance". Recently, it has been reported that a marked decrease in platelet response to clopidogrel is highly associated with the CYP2C19*2 loss-of-function allele, leading to an adverse prognosis.

Ticagrelor is the first reversibly binding, oral, direct acting P2Y12 receptor antagonist. Increasing studies showed that ticagrelor has a more rapid onset of effect and greater inhibition of platelet aggregation compared with clopidogrel. Recently, it has been reported that low-dose ticagrelor either with 90 mg QD or 45 mg BID, was associated with a more potent antiplatelet effect compared with clopidogrel treatment and once daily dose provided similar antiplatelet effect but favorable effect on optimal platelet inhibition compared with twice daily dose. Hiasa et al. identified that ticagrelor 45 mg twice daily was associated with enhanced inhibition of platelet aggregation (IPA) compared with clopidogrel 75 mg once daily in 118 Japanese patients with stable CAD. In our previous study, the investigators found that half-dose ticagrelor produced similar inhibitory effects on platelet aggregation as standard-dose ticagrelor and exerted significantly stronger effects than clopidogrel in patients with ACS and one-quarter standard-dose ticagrelor provided greater degree of platelet inhibition than clopidogrel in patients with stable CAD. Furthermore, standard-dose ticagrelor (180mg loading dose [LD], then 90mg twice daily) has a significant increase in the risk of bleeding and incidence rate of dyspnea, and that higher discontinuation rates due to adverse effects compared to clopidogrel. A recent study demonstrated that maximum plasma concentration and area under the plasma concentration-time curve of ticagrelor (90 mg twice daily) and its active metabolite (AR-C124910XX) tended to be approximately 40% higher in healthy Chinese volunteers compared with Caucasian subjects. Notably, poor drug metabolism of clopidogrel is more common in Asian populations compared with other international regions, due to the prevalence of CYP2C19 reduced-function alleles. The data suggested that a low dose of ticagrelor might be more appropriate for Chinese patients. Therefore, the optimal dose of ticagrelor for Chinese patients with HTPR is increasingly urgent.

So the objectives of this clinical study were to evaluate the effects of optimal dose of ticagrelor(90 mg qd)ticagrelor and double standard-dose clopidogrel on platelet reactivity in Chinese CHD patients with HTPR. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03614832
Study type Interventional
Source First Affiliated Hospital of Harbin Medical University
Contact Guangzhong Liu, PhD
Phone 86-451-85555672
Email lgz2700@126.com
Status Recruiting
Phase Phase 4
Start date May 1, 2018
Completion date October 1, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02808039 - Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial N/A
Completed NCT01961856 - Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor. Phase 3
Recruiting NCT03525145 - Platelet Reactivity And Clinical ThrombotIC Events Study
Completed NCT01463150 - Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT01463163 - Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT01835353 - High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT04001894 - Ticagrelor and Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease Phase 4
Recruiting NCT05773989 - Pharmacodynamic Outcomes in CCS Patients Treated With an Individualized Treatment Strategy Phase 4
Completed NCT01511471 - Ticagrelor in Clopidogrel Resistant Patients Undergoing Chronic Hemodialysis Phase 3
Completed NCT00976196 - Platelet Hyperreactivity Project N/A
Completed NCT00827346 - Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty Phase 2/Phase 3
Recruiting NCT05367336 - Platelet Reactivity With Fentanyl, Morphine, or no Narcotic Early Phase 1
Completed NCT03679091 - Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD. Phase 4
Recruiting NCT05657041 - Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease Phase 2/Phase 3